Merck & Co. Brings Daiichi In As Partner On DLL3-Targeting T-Cell Engager

 
• By Jessica Merrill

The companies are planning to study MK-6070 in combination with an antibody-drug conjugate they are already partnered on, ifinatamab deruxtecan.

Merck and Daiichi are interested in testing combinations with MK-6070 • Source: Shutterstock

More from Deals

More from Business